Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMER-1: Perioperative Pembrolizumab and Lenvatinib in HCC
NCT05185739Phase 2Recruiting
- Sponsor
- University College London
- Start
- Aug 2022
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Pembrolizumab, Lenvatinib and Pembrolizumab + Lenvatinib (3 arms). Primary endpoint: Major pathological response rate at 4 months. Started Aug 2022; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05185739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05185739.